Ionis Pharmaceuticals (IONS)
54.01
+0.62 (1.16%)
Upcoming Events
Latest Headlines
Ionis Pharmaceuticals (IONS) PT Lowered to $89 at Guggenheim
July 21, 2026 6:45 AM - StreetInsider
Raymond James sees potential for beats across biopharma coverage
July 21, 2026 6:12 AM - StreetInsider
Form 4 IONIS PHARMACEUTICALS For: Jul 15 Filed by: Reikes Peter N
July 17, 2026 5:13 PM - SEC Filing
Form 4 IONIS PHARMACEUTICALS For: Jul 15 Filed by: HANTSON LUDWIG
July 17, 2026 5:13 PM - SEC Filing
Form 4 IONIS PHARMACEUTICALS For: Jul 15 Filed by: HERMAN JOAN E
July 17, 2026 5:13 PM - SEC Filing
Form 4 IONIS PHARMACEUTICALS For: Jul 15 Filed by: BERTHELSEN SPENCER R
July 17, 2026 5:12 PM - SEC Filing
Wolfe Research Downgrades Ionis Pharmaceuticals (IONS) to Peerperform
July 16, 2026 2:22 AM - StreetInsider
Form 4 IONIS PHARMACEUTICALS For: Jul 07 Filed by: BENNETT C FRANK
July 15, 2026 11:53 AM - SEC Filing
Ionis to hold second quarter 2026 financial results webcast
July 15, 2026 7:05 AM - BizWire
Increasing unusual option volume: BCE EQPT MDY DOMO CC IONS ARKG FRMM TOI DINO
July 15, 2026 4:24 AM - StreetInsider
Biogen presents Phase 2 data on Alzheimer's drug diranersen at AAIC
July 14, 2026 9:16 AM - StreetInsider
Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
July 14, 2026 9:16 AM - BizWire
H.C. Wainwright Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
July 14, 2026 6:58 AM - StreetInsider
Alnylam Pharmaceuticals (ALNY) PT Raised to $485 at H.C. Wainwright
July 14, 2026 6:54 AM - StreetInsider
Ionis Pharmaceuticals (IONS) PT Lowered to $85 at RBC Capital
July 13, 2026 7:26 AM - StreetInsider
Ionis starts Phase 1-2 trial of ION337 for Dravet syndrome
July 13, 2026 7:01 AM - StreetInsider
Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome
July 13, 2026 7:00 AM - BizWire
Ionis Pharmaceuticals (IONS) PT Lowered to $125 at H.C. Wainwright
July 13, 2026 6:38 AM - StreetInsider
BridgeBio Pharma (BBIO) PT Raised to $120 at H.C. Wainwright
July 13, 2026 6:38 AM - StreetInsider
Ionis Pharmaceuticals (IONS) PT Lowered to $110 at Morgan Stanley
July 10, 2026 8:09 AM - StreetInsider
Ionis Pharmaceuticals (IONS) PT Lowered to $95 at Canaccord
July 10, 2026 6:49 AM - StreetInsider
Ionis Pharmaceuticals (IONS) reaffirms guidance
July 10, 2026 6:06 AM - StreetInsider
Form 8-K IONIS PHARMACEUTICALS For: Jul 09
July 10, 2026 6:04 AM - SEC Filing
Ionis Pharmaceuticals (IONS) PT Lowered to $90 at Barclays
July 10, 2026 5:10 AM - StreetInsider
Form 4 IONIS PHARMACEUTICALS For: Jul 07 Filed by: BENNETT C FRANK
July 9, 2026 7:26 PM - SEC Filing
Form 4 IONIS PHARMACEUTICALS For: Jul 07 Filed by: Diaz Allene M.
July 9, 2026 6:08 PM - SEC Filing
Form 4 IONIS PHARMACEUTICALS For: Jul 07 Filed by: Kordasiewicz Holly B.
July 9, 2026 6:08 PM - SEC Filing
Ionis Pharmaceuticals (IONS) PT Lowered to $100 at Citi
July 9, 2026 4:01 PM - StreetInsider
Form 8-K IONIS PHARMACEUTICALS For: Jul 09
July 9, 2026 2:55 PM - SEC Filing
Ionis Pharmaceuticals (IONS) PT Lowered to $90 at Jefferies
July 9, 2026 12:50 PM - StreetInsider
Ionis Pharmaceuticals (IONS) PT Lowered to $86 at Needham
July 9, 2026 12:40 PM - StreetInsider
Ionis Pharmaceuticals (IONS) PT Lowered to $90 at BofA Securities
July 9, 2026 11:54 AM - StreetInsider
Ionis Pharmaceuticals (IONS) PT Lowered to $94 at TD Cowen
July 9, 2026 11:53 AM - StreetInsider
Ionis Pharmaceuticals (IONS) PT Lowered to $92 at Oppenheimer
July 9, 2026 9:42 AM - StreetInsider
Stifel: 'We expect IONS shares to trade lower today and ALNY shares to be volatile'
July 9, 2026 6:16 AM - StreetInsider
Ionis drug eplontersen misses primary endpoint in heart trial
July 9, 2026 2:00 AM - StreetInsider
Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy
July 9, 2026 2:00 AM - BizWire
Form 144 IONIS PHARMACEUTICALS Filed by: Diaz Allene M.
July 7, 2026 4:33 PM - SEC Filing
Form 144 IONIS PHARMACEUTICALS Filed by: Kordasiewicz Holly B.
July 7, 2026 4:30 PM - SEC Filing
Form 144 IONIS PHARMACEUTICALS Filed by: BENNETT C FRANK
July 7, 2026 4:29 PM - SEC Filing
Form 4 IONIS PHARMACEUTICALS For: Jul 01 Filed by: YANG MICHAEL J.
July 6, 2026 6:51 PM - SEC Filing
Form 4 IONIS PHARMACEUTICALS For: Jul 01 Filed by: LOSCALZO JOSEPH
July 6, 2026 6:50 PM - SEC Filing
Form 4 IONIS PHARMACEUTICALS For: Jul 01 Filed by: HERMAN JOAN E
July 6, 2026 6:50 PM - SEC Filing
Form 4 IONIS PHARMACEUTICALS For: Jul 01 Filed by: KLEIN JOSEPH III
July 6, 2026 6:49 PM - SEC Filing
Form 4 IONIS PHARMACEUTICALS For: Jul 01 Filed by: Hayden Michael R
July 6, 2026 6:45 PM - SEC Filing
Form 4 IONIS PHARMACEUTICALS For: Jul 01 Filed by: Diaz Allene M.
July 6, 2026 6:45 PM - SEC Filing
Form 4 IONIS PHARMACEUTICALS For: Jul 01 Filed by: BERTHELSEN SPENCER R
July 6, 2026 6:44 PM - SEC Filing
Ionis completes enrollment in Phase 3 Angelman syndrome study
July 6, 2026 7:00 AM - StreetInsider
Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome
July 6, 2026 7:00 AM - BizWire
Form 144 IONIS PHARMACEUTICALS Filed by: KLEIN JOSEPH III
July 1, 2026 5:29 PM - SEC Filing
Form 4 IONIS PHARMACEUTICALS For: Jun 26 Filed by: Baroldi Joseph
June 30, 2026 5:49 PM - SEC Filing
Form 4 IONIS PHARMACEUTICALS For: Jun 26 Filed by: O'NEIL PATRICK R.
June 30, 2026 5:48 PM - SEC Filing
Form 4 IONIS PHARMACEUTICALS For: Jun 26 Filed by: Schneider Eugene
June 30, 2026 5:48 PM - SEC Filing
Form 4 IONIS PHARMACEUTICALS For: Jun 24 Filed by: Monia Brett P
June 26, 2026 7:10 PM - SEC Filing
Form 4 IONIS PHARMACEUTICALS For: Jun 25 Filed by: Swayze Eric
June 26, 2026 7:10 PM - SEC Filing
Form 144 IONIS PHARMACEUTICALS Filed by: Baroldi Mariana
June 26, 2026 5:49 PM - SEC Filing
Form 144 IONIS PHARMACEUTICALS Filed by: O'NEIL PATRICK R.
June 26, 2026 5:48 PM - SEC Filing
Form 144 IONIS PHARMACEUTICALS Filed by: Schneider Eugene
June 26, 2026 5:43 PM - SEC Filing
Form 144 IONIS PHARMACEUTICALS Filed by: Swayze Eric
June 25, 2026 6:54 PM - SEC Filing
Needham Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
June 25, 2026 7:12 AM - StreetInsider
Ionis Pharmaceuticals (IONS) PT Raised to $130 at H.C. Wainwright
June 25, 2026 6:46 AM - StreetInsider
Oppenheimer Reiterates Outperform Rating on Ionis Pharmaceuticals (IONS)
June 25, 2026 3:33 AM - StreetInsider
Ionis licenses zilganersen to Recordati for ex-U.S. markets
June 25, 2026 2:59 AM - StreetInsider
Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.
June 25, 2026 2:59 AM - BizWire
Form 8-K IONIS PHARMACEUTICALS For: Jun 24
June 24, 2026 3:49 PM - SEC Filing
FDA approves Ionis drug Tryngolza for severe hypertriglyceridemia
June 24, 2026 2:39 PM - StreetInsider
TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)
June 24, 2026 2:37 PM - BizWire
Form 4 IONIS PHARMACEUTICALS For: Jun 12 Filed by: Kordasiewicz Holly B.
June 16, 2026 5:26 PM - SEC Filing
Form 4 IONIS PHARMACEUTICALS For: Jun 15 Filed by: BERTHELSEN SPENCER R
June 16, 2026 5:26 PM - SEC Filing
Form 144 IONIS PHARMACEUTICALS Filed by: BERTHELSEN SPENCER R
June 15, 2026 10:18 AM - SEC Filing
Form 144 IONIS PHARMACEUTICALS Filed by: Kordasiewicz Holly B.
June 12, 2026 4:29 PM - SEC Filing
Form 8-K IONIS PHARMACEUTICALS For: Jun 12
June 12, 2026 2:20 PM - SEC Filing
Form 4 IONIS PHARMACEUTICALS For: Jun 04 Filed by: Reikes Peter N
June 8, 2026 5:00 PM - SEC Filing
Form 4 IONIS PHARMACEUTICALS For: Jun 04 Filed by: HANTSON LUDWIG
June 8, 2026 4:59 PM - SEC Filing
Form 3 IONIS PHARMACEUTICALS For: Jun 04 Filed by: Reikes Peter N
June 8, 2026 4:59 PM - SEC Filing
Form 3 IONIS PHARMACEUTICALS For: Jun 04 Filed by: HANTSON LUDWIG
June 8, 2026 4:59 PM - SEC Filing
Form 8-K IONIS PHARMACEUTICALS For: Jun 04
June 8, 2026 12:50 PM - SEC Filing
Ionis appoints Ludwig Hantson to board of directors
June 8, 2026 7:00 AM - StreetInsider
Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors
June 8, 2026 7:00 AM - BizWire
Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses
June 4, 2026 7:00 AM - BizWire
Form 4 IONIS PHARMACEUTICALS For: Jun 01 Filed by: BERTHELSEN SPENCER R
June 3, 2026 5:34 PM - SEC Filing
Form 144 IONIS PHARMACEUTICALS Filed by: BERTHELSEN SPENCER R
June 1, 2026 10:48 AM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
June 1, 2026 6:57 AM - StreetInsider
JPMorgan says large-cap biotech is back as profits and pipelines fuel upside
May 28, 2026 4:07 PM - StreetInsider
Form 8-K IONIS PHARMACEUTICALS For: May 28
May 28, 2026 12:41 PM - SEC Filing
Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
May 28, 2026 4:45 AM - BizWire
H.C. Wainwright Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
May 27, 2026 6:44 AM - StreetInsider
Wolfe: 'Arrowhead Q3 data in acute pancreatitis will be the next big event to readthrough to Ionis. We see 74% odds of IONS stock down, 26% odds up'
May 26, 2026 5:33 AM - StreetInsider
JPMorgan Reinstates Ionis Pharmaceuticals (IONS) at Overweight
May 20, 2026 4:30 AM - StreetInsider
Citi Starts Ionis Pharmaceuticals (IONS) at Buy
May 18, 2026 4:15 PM - StreetInsider
Form 4 IONIS PHARMACEUTICALS For: May 13 Filed by: Monia Brett P
May 15, 2026 6:15 PM - SEC Filing
Form SCHEDULE 13G/A IONIS PHARMACEUTICALS Filed by: T. Rowe Price Investment Management, Inc.
May 15, 2026 10:07 AM - SEC Filing
Form SCHEDULE 13G/A IONIS PHARMACEUTICALS Filed by: Capital World Investors
May 14, 2026 1:56 PM - SEC Filing
Biogen advances IONIS alzheimer's drug after phase 2 study shows cognitive benefit
May 14, 2026 7:05 AM - StreetInsider
Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer�
May 14, 2026 7:05 AM - BizWire
Form 144 IONIS PHARMACEUTICALS Filed by: Monia Brett P
May 13, 2026 5:20 PM - SEC Filing
Form 4 IONIS PHARMACEUTICALS For: May 04 Filed by: LOSCALZO JOSEPH
May 6, 2026 5:27 PM - SEC Filing
Form 4 IONIS PHARMACEUTICALS For: May 01 Filed by: KLEIN JOSEPH III
May 5, 2026 4:31 PM - SEC Filing
Form 144 IONIS PHARMACEUTICALS Filed by: LOSCALZO JOSEPH
May 4, 2026 6:06 PM - SEC Filing
Ionis to host 2026 virtual Annual Meeting of Stockholders
May 4, 2026 7:05 AM - BizWire
Ionis to present at upcoming investor conferences
May 1, 2026 7:05 AM - BizWire
Form 4 IONIS PHARMACEUTICALS For: Apr 28 Filed by: Baroldi Joseph
April 30, 2026 4:26 PM - SEC Filing
Form SCHEDULE 13G IONIS PHARMACEUTICALS Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 30, 2026 11:08 AM - SEC Filing
Ionis Pharmaceuticals (IONS) PT Raised to $100 at RBC Capital
April 30, 2026 8:39 AM - StreetInsider
Ionis Pharmaceuticals (IONS) PT Raised to $96 at Bernstein SocGen Group
April 30, 2026 7:36 AM - StreetInsider
Ionis Pharmaceuticals (IONS) PT Raised to $125 at H.C. Wainwright
April 30, 2026 6:50 AM - StreetInsider
Ionis Pharmaceuticals (IONS) PT Raised to $115 at Barclays
April 30, 2026 6:01 AM - StreetInsider
Ionis Pharmaceuticals (IONS) PT Raised to $110 at Oppenheimer
April 29, 2026 5:40 PM - StreetInsider
Ionis Pharmaceuticals (IONS) PT Raised to $86 at Stifel
April 29, 2026 4:10 PM - StreetInsider
Form 10-Q IONIS PHARMACEUTICALS For: Mar 31
April 29, 2026 2:34 PM - SEC Filing
Ionis Pharmaceuticals (IONS) Tops Q1 EPS by 29c ; Offers Guidance
April 29, 2026 7:10 AM - StreetInsider
Form 8-K IONIS PHARMACEUTICALS For: Apr 29
April 29, 2026 7:01 AM - SEC Filing
Ionis reports first quarter 2026 financial results and highlights progress on key programs
April 29, 2026 7:00 AM - BizWire
Form 144 IONIS PHARMACEUTICALS Filed by: Baroldi Joseph
April 28, 2026 4:13 PM - SEC Filing
FDA accepts GSK's bepirovirsen for priority review in hepatitis B treatment
April 28, 2026 2:06 AM - StreetInsider
Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B
April 28, 2026 2:06 AM - BizWire
U.S. Biotech stocks: Q1 earnings previews
April 26, 2026 8:00 PM - StreetInsider
Full Article List
